IBIO

iBio Inc

0.8210

Oct 20 • 3:59 PM ET +0.0609 (8.01%)

0.8624

Aftermarket • 7:30 PM ET +0.0414 (5.04%)

Healthcare Biotechnology USA Nano NASD

Peers: KROS SRRK VERU ABSI ABCL BMEA CRBP ALT SEPN XBIT

| Held by: VTI VXF IWC

Scroll to Statements

Index	-
Market Cap	49.96M
Enterprise Value	-35.88M
Income	-33.04M
Sales	0.10M
Book/sh	1.54
Cash/sh	1.45
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	23
IPO	Aug 19, 2008

P/E	-
Forward P/E	-
PEG	-
P/S	499.56
P/B	0.53
P/C	0.57
P/FCF	-
EV/EBITDA	-
EV/Sales	-358.84
Quick Ratio	7.85
Current Ratio	7.85
Debt/Eq	0.03
LT Debt/Eq	0.02
Option/Short	No / Yes

EPS (ttm)	-0.45
EPS next Y	-0.59
EPS next Q	-0.07
EPS this Y	-23.21%
EPS next Y	-49.64%
EPS next 5Y	-
EPS past 3/5Y	85.59% 64.94%
Sales past 3/5Y	- -46.91%
EPS Y/Y TTM	74.04%
Sales Y/Y TTM	-75.00%
EPS Q/Q	39.47%
Sales Q/Q	-100.00%
Earnings	Aug 28 BMO
EPS/Sales Surpr.	27.85% -

Insider Own	8.54%
Insider Trans	0.00%
Inst Own	64.94%
Inst Trans	16.62%
ROA	-54.04%
ROE	-65.70%
ROIC	-37.82%
Gross Margin	-930.00%
Oper. Margin	-30138.00%
Profit Margin	-33044.00%
SMA20	-17.72%
SMA50	-31.84%
SMA200	-53.26%
Trades

Shs Outstand	55.70M
Shs Float	55.66M
Short Float	7.55%
Short Ratio	5.88
Short Interest	4.20M
52W High	3.82 -78.51%
52W Low	0.73 12.04%
Volatility	9.23% 8.94%
ATR (14)	0.08
RSI (14)	28.99
Beta	1.44
Rel Volume	3.10
Avg Volume	714.13K
Volume	2,216,009

Perf Week	5.01%
Perf Month	-34.84%
Perf Quarter	-40.51%
Perf Half Y	-57.24%
Perf YTD	-57.46%
Perf Year	-8.06%
Perf 3Y	-86.54%
Perf 5Y	-99.81%
Perf 10Y	-99.97%
Recom	1.14
Target Price	5.60
Prev Close	0.76
Price	0.82
Change %	8.01%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-17-26	Initiated	H.C. Wainwright	Buy	$7
Jun-08-26	Initiated	Raymond James	Outperform	$5
Jun-05-26	Initiated	B. Riley Securities	Buy	$6
Oct-21-25	Initiated	Oppenheimer	Outperform	$5
Oct-17-25	Initiated	Leerink Partners	Outperform	$2
May-28-24	Initiated	Chardan Capital Markets	Buy	$5
Nov-29-21	Initiated	JMP Securities	Mkt Outperform	$1.50
Jan-22-21	Initiated	Cantor Fitzgerald	Overweight	$3
Jun-26-20	Initiated	Alliance Global Partners	Buy	$2.55

Oct-13-26 07:00AM	iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610's Potential to Preserve Muscle in Combination with GLP-1 Therapy (GlobeNewswire) -13.44%
Sep-01-26 04:30PM	iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference (GlobeNewswire)
Aug-28-26 07:00AM	iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-04-26 07:00AM	iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer (GlobeNewswire)
Jul-01-26 07:00AM	iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study (GlobeNewswire)
04:01PM	Loading…
Jun-02-26 04:01PM	iBio to Participate in Upcoming Healthcare Investor Conferences (GlobeNewswire) -6.88%
07:00AM	iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity (GlobeNewswire)
May-12-26 04:05PM	iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-26 07:15AM	iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors (GlobeNewswire)
Apr-08-26 07:00AM	iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia (GlobeNewswire) +6.16%
Mar-16-26 04:30PM	iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire)
Mar-09-26 07:00AM	iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss (GlobeNewswire)
Feb-24-26 07:00AM	iBio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-10-26 04:05PM	iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -5.81%
Feb-03-26 10:00AM	CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
10:00AM	Loading…
Feb-02-26 10:00AM	iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks) +9.52%
Jan-09-26 07:00AM	iBio Announces $26 Million Private Placement (GlobeNewswire) +14.89%
Nov-24-25 04:15PM	iBio to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire) +5.71% +5.41%
Nov-12-25 05:15PM	iBio, Inc. (IBIO) Reports Q1 Loss (Zacks) -8.00%
04:01PM	iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-30-25 07:00AM	iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance (GlobeNewswire)
Oct-23-25 07:00AM	iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference (GlobeNewswire) -8.63%
Oct-21-25 07:00AM	iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek and PEGS Europe 2025 (GlobeNewswire) +24.30%
Sep-05-25 07:30AM	iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-25-25 07:00AM	iBio Announces Closing of $50 Million Public Offering (GlobeNewswire) +6.93%
Aug-19-25 08:01AM	iBio Announces Pricing of $50 Million Public Offering (GlobeNewswire)
Aug-18-25 04:01PM	iBio Announces Proposed Public Offering (GlobeNewswire)
Jun-24-25 07:00AM	iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results (GlobeNewswire)
Jun-23-25 04:15PM	iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call (GlobeNewswire) -7.60%
Jun-16-25 07:00AM	iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment (GlobeNewswire) -5.83%
08:00AM	Loading…
May-05-25 08:00AM	iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model (GlobeNewswire)
May-02-25 08:00AM	iBio Reports Fiscal Third Quarter 2025 Financial Results (GlobeNewswire)
Apr-29-25 01:43PM	iBio Raises $6.2 Million Through Warrant Inducement Transaction (GlobeNewswire)
Apr-22-25 08:00AM	iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio (GlobeNewswire) -17.43%
Apr-07-25 07:00AM	iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline (GlobeNewswire) -53.18%
Apr-01-25 10:00AM	iBio, Inc. Common Stock (IBIO): Among Stocks Insiders Were Buying In Q1 2025 (Insider Monkey)
Feb-19-25 04:05PM	iBio to Begin Trading on the Nasdaq Stock Exchange (GlobeNewswire) -5.71%
Feb-17-25 04:38PM	Is Ibio, Inc. (IBIO) Among Stocks Insiders Are Buying This Year? (Insider Monkey)
Feb-10-25 04:05PM	iBio Reports Fiscal Second Quarter 2025 Financial Results (GlobeNewswire) -8.06% -7.31%
Jan-13-25 07:00AM	iBio Announces New Investments from Board Members and Officers (GlobeNewswire)
Jan-07-25 07:00AM	iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio (GlobeNewswire) +10.16%
Jan-03-25 07:58AM	iBio Expands Pipeline with New Antibody Agreement (TipRanks)
Jan-02-25 09:24AM	Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed Platform (Benzinga)
07:00AM	iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio (GlobeNewswire)
Nov-25-24 08:00AM	iBio Strengthens Board with Appointment of Two New Independent Directors (GlobeNewswire)
Nov-12-24 04:05PM	iBio Reports Fiscal First Quarter 2025 Financial Results (GlobeNewswire) -9.02%
Oct-10-24 08:00AM	iBio and AstralBio Provide Update on Myostatin Program for Obesity (GlobeNewswire) -7.75%
Sep-20-24 04:05PM	iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -6.09%
Sep-03-24 07:00AM	iBio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-12-24 04:30PM	iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development (GlobeNewswire) +23.42%
Jun-03-24 07:00AM	iBio Closes Sale of Manufacturing Facility in Texas (GlobeNewswire)
May-13-24 04:05PM	iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-05-24 02:35PM	3 Healthcare Stocks Short Sellers Are Prescribing for Trouble (InvestorPlace) -15.26%
Mar-27-24 07:00AM	iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases (GlobeNewswire) +192.17%
Mar-26-24 07:35PM	iBio Announces $15.0 Million Private Placement (GlobeNewswire) +5.02%
Mar-24-24 03:54PM	12 Best Biotech Penny Stocks to Invest In (Insider Monkey)
Feb-26-24 07:45AM	iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka (GlobeNewswire)
Jan-16-24 08:15AM	iBio Announces Participation in 23rd Annual PepTalk Conference (GlobeNewswire)
Dec-26-23 07:15AM	iBio Amends and Extends Maturity of Credit Agreement (GlobeNewswire)
Dec-05-23 08:00AM	iBio, Inc. Announces Pricing of $4.5 Million Public Offering (GlobeNewswire) -50.00%
Nov-27-23 05:20PM	iBio Announces Reverse Stock Split (GlobeNewswire) -31.03%
Nov-01-23 08:24AM	iBio Further Expands Tech Stack with ShieldTx; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific (GlobeNewswire)
Oct-10-23 08:00AM	iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics (GlobeNewswire) +7.14%
Oct-02-23 06:45AM	iBio Explains Recent Filing of Registration Statement (GlobeNewswire)
Sep-27-23 04:19PM	iBio Announces Filing of 2023 Annual Report on SEC Form 10-K (GlobeNewswire)
Sep-21-23 04:05PM	iBio Announces Amendment to Credit Agreement with Woodforest (GlobeNewswire)
Aug-14-23 04:15PM	iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development (GlobeNewswire) -6.53%
Jun-27-23 08:00AM	iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Companys Next Stage of Growth (GlobeNewswire) -7.38%
Jun-20-23 08:25AM	3 Millionaire-Maker Biotech Stocks to Buy and Hold Forever (InvestorPlace)
Jun-12-23 04:15PM	iBio Forges Research Collaboration with the National Institutes of Health (GlobeNewswire)
Jun-06-23 08:00AM	iBio Expands Tech Stack with EngageTx; Adds TROP-2 Bispecific to Development Pipeline (GlobeNewswire) +9.25%
May-09-23 04:30PM	iBio to Participate in the JMP Securities Life Sciences Conference (GlobeNewswire)
Apr-04-23 04:05PM	iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform (GlobeNewswire) -12.35% -18.12%
Mar-31-23 08:10AM	iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing (GlobeNewswire)
Feb-16-23 04:48PM	iBio Announces MUC16 as its Latest Immune-Oncology Target Program (GlobeNewswire) -11.86% +97.28%
Jan-05-23 08:00AM	iBio Announces Issuance of U.S. Patent Covering AI-Engineered Epitope Discovery Engine (GlobeNewswire) -5.23%
Dec-09-22 04:05PM	iBio Announces Closing of $3.5 Million Underwritten Public Offering (GlobeNewswire) -7.16%
Dec-06-22 11:27PM	iBio Announces Pricing of $3.5 Million Underwritten Public Offering (GlobeNewswire) -57.88%
04:01PM	iBio Announces Proposed Underwritten Public Offering (GlobeNewswire)
08:00AM	iBio to Participate in the JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Dec-05-22 08:00AM	iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022 (GlobeNewswire)
Dec-02-22 04:30PM	iBio Announces CEO Departure (GlobeNewswire) +6.25%
Nov-03-22 08:00AM	iBio Accelerates Transformation to AI-Powered Biotech (GlobeNewswire) -9.71%
Oct-27-22 06:40PM	7 Penny Stocks to Sell Pronto Before a Painful Downturn (InvestorPlace) -5.14%
Sep-30-22 11:48AM	3 Healthcare Stocks to Sell Before They Die (InvestorPlace) -6.53%
Sep-27-22 04:30PM	Edited Transcript of IBIO.A earnings conference call or presentation 27-Sep-22 8:30pm GMT (Thomson Reuters StreetEvents) -32.28%
04:10PM	iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Sep-21-22 08:30AM	iBio Acquires RubrYc Therapeutics AI Drug Discovery Platform and Pipeline (GlobeNewswire) +12.18%
Aug-16-22 09:00AM	iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate (GlobeNewswire)
May-18-22 08:00AM	iBio to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire) -7.55%
May-16-22 10:25AM	iBio (IBIO) Q3 2022 Earnings Call Transcript (Motley Fool)
May-12-22 04:05PM	iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +10.12% -7.00%
May-09-22 08:00AM	iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer (GlobeNewswire)
May-05-22 04:30PM	iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022 (GlobeNewswire) -8.38%
May-02-22 08:00AM	iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants (GlobeNewswire)
Mar-11-22 08:00AM	iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire)
Feb-14-22 04:05PM	iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-07-22 04:30PM	iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022 (GlobeNewswire)
Jan-26-22 11:21AM	iBio Advances Its Vaccine Program for Multi-Variant COVID-19 Disease (Benzinga)
09:00AM	iBio Announces Progression of Vaccine Program for Multi-Variant COVID-19 Disease (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Banjak Marc	Chief Legal Officer	Mar 26 '26	Buy	1.65	13,934	23,055	25,000	Mar 27 04:05 PM
Duran Felipe	Chief Financial Officer	Mar 19 '26	Buy	2.02	24,835	50,132	35,974	Mar 23 07:31 AM
Brenner Martin	See Remarks	Mar 19 '26	Buy	2.02	12,336	24,919	30,652	Mar 23 07:30 AM

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

Ph.D.Dr. Martin B. Brenner D.V.M.

CFO & Principal Accounting OfficerMr. Felipe Duran

Chief Legal OfficerMr. Marc Banjak J.D.

Chief Medical OfficerDr. Molly Carr M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IBIO

iBio Inc

Upgrade your Finviz experience